Zhejiang Health Creation Bio-Technology Co., Ltd. announced that it will receive an equity round of funding from returning investor Zhejiang Medicine Co., Ltd. (SHSE:600216) on October 27, 2020. Post closing, investor will retain its 100% stake in the transaction.